FDA approves Protein Sciences quadrivalent flu vaccine

By Dan Stanton contact

- Last updated on GMT

Image: iStock/Baluchis
Image: iStock/Baluchis

Related tags: Influenza, Vaccine, Influenza vaccine

The US FDA has approved a quadrivalent formulation of Protein Sciences’ vaccine, Flublok, produced without eggs or the influenza virus.

According to the vaccine maker, Flublok Quadrivalent is the first high antigen content quadrivalent flu to be approved by the US Food and Drug Administration (FDA).

“The US has been trending toward the use of quadrivalent flu vaccines in recent years,”​ said Manon Cox, CEO of Protein Sciences Corporation. “We are looking forward to launching the vaccine next year and, in the meantime, continuing to make trivalent Flublok available this year.”

The vaccine protects against four strains of influenza: three of the same strains found in trivalent Flublok plus an additional B strain, and like the trivalent product is not reliant on traditional manufacturing processes.

Rather than use production methods that involve growing live influenza virus in hens eggs, Protein Sciences employs an insect virus-based expression system to make large quantities of viral hemagglutinin, the protein that elicits the strongest immune response

Such an approach removes the risk of contamination from the live virus or hens egg and offers significant time advantages, the firm previously told this publication​.

We can manufacture vaccine in significantly less time  - 2-3 months vs. 6 months - and that can be shortened even further to a few weeks if we already have recombinant baculoviruses made/stored that express the desired hemagglutinin protein​,”spokeswoman Rachael Felberbaum said.

Protein Sciences’ manufacturing plant is the Pearl River facility​ in New York, refitted in just ten weeks after the firm acquired the site from Pfizer in 2012.

Related news

Show more

Related products

show more

Small-Scale Cell Culture Perfusion Process

Small-Scale Cell Culture Perfusion Process

Eppendorf for Bioprocess – Solutions that grow with you | 29-Mar-2019 | Application Note

Perfusion cell culture processes promise advantages for industrial bioprocessing, like saving space, increasing volumetric productivity, achieving more...

Cultivation of 3D Cell Aggregates in Perfusion

Cultivation of 3D Cell Aggregates in Perfusion

Eppendorf for Bioprocess – Solutions that grow with you | 17-Sep-2018 | Application Note

3D cell aggregates are of great interest for applications like disease modeling and manufacturing of stem cell-based products. Read more about the cultivation...

Nifty Biosimilar

Nifty Biosimilar

UGA Biopharma | 13-Mar-2018 | Research Study

Aflibercept (Zaltrap®) is a recombinant fusion protein with complex post-translational modifications. Therefore deep understanding of biosimilar development...

Related suppliers

Follow us

Products

View more

Webinars